Product logins

Find logins to all Clarivate products below.


Biologics in oncology, immunology, nephrology and endocrinology generated over $70 billion in 2015, nearly all attributed to branded biologics. As more branded agents lose patent protection and more biosimilars enter the market, branded biologics are expected to lose considerable market share, both by declining use but also price reductions. We present our forecasts for 36 reference brands and their biosimilars, over the 2015-2025 period by therapeutic area, molecule, and region.

Related Market Assessment Reports

Report
Biosimilars – Forecast – Immunology
In 2023, sales of branded biologics in immunology exceeded $64 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Major-market sales of biosimilars in this…
Report
Biosimilars – Forecast – Oncology
In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5…
Report
Biosimilars – Forecast – Forecast Methodology and General Market Assumptions
In 2023, sales of branded biologics for oncology, immunology, endocrinology, ophthalmology, neurology, osteoporosis, and respiratory indications exceeded $150 billion in the major pharmaceutical…
Report
Biosimilars – Forecast – Ophthalmology
In 2023, sales of branded biologics in ophthalmology exceeded $9.2 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033 forecast period…
Report
Biosimilars – Forecast – Respiratory
In 2023, sales of branded biologics for respiratory indications totaled about $6.6 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout our 2023-2033…